摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[4-(phenylthio)benzyl]phthalimide | 880157-41-5

中文名称
——
中文别名
——
英文名称
N-[4-(phenylthio)benzyl]phthalimide
英文别名
2-[(4-Phenylsulfanylphenyl)methyl]isoindole-1,3-dione
N-[4-(phenylthio)benzyl]phthalimide化学式
CAS
880157-41-5
化学式
C21H15NO2S
mdl
——
分子量
345.422
InChiKey
PMWUPRMKHUASDZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    62.7
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • Purinenucleoside derivative modified in 8-position and medical use thereof
    申请人:Tatani Kazuya
    公开号:US20070179115A1
    公开(公告)日:2007-08-02
    The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.
    本发明提供了一种用于与血浆尿酸平异常相关疾病的8-修饰嘌呤核苷衍生物。以下式(I)所代表的一种8-修饰嘌呤核苷衍生物、其前药或药用盐、或其合物或溶剂化合物,对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗具有用处。在该式中,n为1或2;RA是氢原子或羟基;R1是氢原子、羟基、醇基、基或原子;环J代表可选地取代的2-基,或由以下一般式(II)所代表的基团,其中Y代表单键或连接基团;环Z代表可选地取代的芳基或杂环芳基等;而R2至R4、P1和Q代表卤素原子、基或类似物。
  • PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF
    申请人:Tatani Kazuya
    公开号:US20100249054A9
    公开(公告)日:2010-09-30
    The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.
    本发明提供了一种8-修饰嘌呤核苷衍生物,用于与血浆尿酸平异常相关的疾病。公式(I)所表示的8-修饰嘌呤核苷衍生物,其前体药物或其药学上可接受的盐,或其合物或溶剂化物,可用于痛风、高尿酸血症、泌尿系结石、高尿酸性肾病等的预防或治疗。在公式中,n为1或2;RA是氢原子或羟基;R1是氢原子、羟基、醇基、基或原子;环J表示可选取的2-基团,或由以下通式(II)所表示的基团,其中Y表示单键或连接基团;环Z表示可选取的芳基团或杂环芳基团等;R2到R4、P1和Q表示卤素原子、基或类似物。
  • PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:EP1813623A1
    公开(公告)日:2007-08-01
    The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.
    本发明提供了一种 8-修饰嘌呤核苷衍生物,可用于治疗与血浆尿酸平异常有关的疾病。下式(I)代表的8-修饰嘌呤核苷衍生物、其原药或其药学上可接受的盐,或其合物或溶解物可用于预防或治疗痛风、高尿酸血症、尿路结石、高尿酸血症肾病或类似疾病。 式中,n 是 1 或 2;RA 是氢原子或羟基;R1 是氢原子、羟基、醇基、基或原子;环 J 代表任选取代的 2-基,或下式通式(II)所代表的基团,其中 Y 代表单键或连接基团;环 Z 代表任选取代的芳基或杂芳基或类似基团;以及 R2 至 R4、P1 和 Q 代表卤素原子、基或类似基团。
  • US7795236B2
    申请人:——
    公开号:US7795236B2
    公开(公告)日:2010-09-14
查看更多

同类化合物

(1Z,3Z)-1,3-双[[((4S)-4,5-二氢-4-苯基-2-恶唑基]亚甲基]-2,3-二氢-5,6-二甲基-1H-异吲哚 鲁拉西酮杂质33 鲁拉西酮杂质07 马吲哚 颜料黄110 顺式-六氢异吲哚盐酸盐 顺式-2-[(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)甲基]-N-乙基-1-苯基环丙烷甲酰胺 顺式-2,3,3a,4,7,7a-六氢-1H-异吲哚 顺-N-(4-氯丁烯基)邻苯二甲酰亚胺 降莰烷-2,3-二甲酰亚胺 降冰片烯-2,3-二羧基亚胺基对硝基苄基碳酸酯 降冰片烯-2,3-二羧基亚胺基叔丁基碳酸酯 阿胍诺定 阿普斯特降解杂质 阿普斯特杂质FA 阿普斯特杂质68 阿普斯特杂质29 阿普斯特杂质27 阿普斯特杂质26 阿普斯特杂质19 阿普斯特杂质08 阿普斯特杂质03 阿普斯特杂质 阿普斯特二聚体杂质 阿普斯特 防焦剂MTP 铝酞菁 铁(II)1,2,3,4,8,9,10,11,15,16,17,18,22,23,24,25-十六氟-29H,31H-酞菁 铁(II)2,9,16,23-四氨基酞菁 钠S-(2-{[2-(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙基]氨基}乙基)氢硫代磷酸酯 酞酰亚胺-15N钾盐 酞菁锡 酞菁二氯化硅 酞菁 单氯化镓(III) 盐 酞美普林 邻苯二甲酸亚胺 邻苯二甲酰基氨氯地平 邻苯二甲酰亚胺,N-((吗啉)甲基) 邻苯二甲酰亚胺阴离子 邻苯二甲酰亚胺钾盐 邻苯二甲酰亚胺钠盐 邻苯二甲酰亚胺观盐 邻苯二亚胺甲基磷酸二乙酯 那伏莫德 过氧化氢,2,5-二氢-5-苯基-3H-咪唑并[2,1-a]异吲哚-5-基 达格吡酮 诺非卡尼 螺[环丙烷-1,1'-异二氢吲哚]-3'-酮 螺[异吲哚啉-1,4'-哌啶]-3-酮盐酸盐 葡聚糖凝胶G-25